Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Targeting uPAR by CRISPR/Cas9 System Attenuates Cancer Malignancy and Multidrug Resistance.

Wang K, Xing ZH, Jiang QW, Yang Y, Huang JR, Yuan ML, Wei MN, Li Y, Wang ST, Liu K, Shi Z.

Front Oncol. 2019 Feb 27;9:80. doi: 10.3389/fonc.2019.00080. eCollection 2019.

2.

Targeting ABCB1-mediated tumor multidrug resistance by CRISPR/Cas9-based genome editing.

Yang Y, Qiu JG, Li Y, Di JM, Zhang WJ, Jiang QW, Zheng DW, Chen Y, Wei MN, Huang JR, Wang K, Shi Z.

Am J Transl Res. 2016 Sep 15;8(9):3986-3994. eCollection 2016.

3.
4.

Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.

Magnussen SN, Hadler-Olsen E, Costea DE, Berg E, Jacobsen CC, Mortensen B, Salo T, Martinez-Zubiaurre I, Winberg JO, Uhlin-Hansen L, Svineng G.

BMC Cancer. 2017 May 19;17(1):350. doi: 10.1186/s12885-017-3349-7.

5.

Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance.

LeBeau AM, Sevillano N, King ML, Duriseti S, Murphy ST, Craik CS, Murphy LL, VanBrocklin HF.

Theranostics. 2014 Jan 18;4(3):267-79. doi: 10.7150/thno.7323. eCollection 2014.

6.

Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.

Iwamoto J, Mizokami Y, Takahashi K, Nakajima K, Ohtsubo T, Miura S, Narasaka T, Takeyama H, Omata T, Shimokobe K, Ito M, Takehara H, Matsuoka T.

Scand J Gastroenterol. 2005 Jul;40(7):783-93.

PMID:
16109653
7.

Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.

Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP, Ellis LM.

Cancer Res. 2005 Sep 1;65(17):7775-81.

8.

Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.

Holst-Hansen C, Johannessen B, Høyer-Hansen G, Rømer J, Ellis V, Brünner N.

Clin Exp Metastasis. 1996 May;14(3):297-307.

PMID:
8674284
9.

Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.

Xue A, Xue M, Jackson C, Smith RC.

Int J Biochem Cell Biol. 2009 Aug-Sep;41(8-9):1731-8. doi: 10.1016/j.biocel.2009.03.004. Epub 2009 Mar 21.

PMID:
19433314
10.

Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.

Bauer TW, Fan F, Liu W, Johnson M, Parikh NU, Parry GC, Callahan J, Mazar AP, Gallick GE, Ellis LM.

Ann Surg. 2005 May;241(5):748-56; discussion 756-8.

11.
12.

Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch -1 receptor.

Raghu H, Gondi CS, Dinh DH, Gujrati M, Rao JS.

Mol Cancer. 2011 Oct 17;10:130. doi: 10.1186/1476-4598-10-130.

13.

uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.

Huber MC, Mall R, Braselmann H, Feuchtinger A, Molatore S, Lindner K, Walch A, Gross E, Schmitt M, Falkenberg N, Aubele M.

BMC Cancer. 2016 Aug 8;16:615. doi: 10.1186/s12885-016-2663-9.

15.

Urokinase-type plasminogen activator receptor promotes proliferation and invasion with reduced cisplatin sensitivity in malignant mesothelioma.

Wang S, Jiang L, Han Y, Chew SH, Ohara Y, Akatsuka S, Weng L, Kawaguchi K, Fukui T, Sekido Y, Yokoi K, Toyokuni S.

Oncotarget. 2016 Oct 25;7(43):69565-69578. doi: 10.18632/oncotarget.11829.

16.

Identification of uPAR-positive chemoresistant cells in small cell lung cancer.

Gutova M, Najbauer J, Gevorgyan A, Metz MZ, Weng Y, Shih CC, Aboody KS.

PLoS One. 2007 Feb 28;2(2):e243.

17.

Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.

Albo D, Berger DH, Rothman VL, Tuszynski GP.

J Surg Res. 1999 Apr;82(2):331-8.

PMID:
10090848
18.

FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator system.

Huang C, Xie D, Cui J, Li Q, Gao Y, Xie K.

Clin Cancer Res. 2014 Mar 15;20(6):1477-88. doi: 10.1158/1078-0432.CCR-13-2311. Epub 2014 Jan 22.

19.

Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration.

Dutta S, Bandyopadhyay C, Bottero V, Veettil MV, Wilson L, Pins MR, Johnson KE, Warshall C, Chandran B.

Mol Oncol. 2014 May;8(3):483-507. doi: 10.1016/j.molonc.2013.12.017. Epub 2014 Jan 4.

20.

HAX1 Augments Cell Proliferation, Migration, Adhesion, and Invasion Induced by Urokinase-Type Plasminogen Activator Receptor.

Mekkawy AH, Morris DL, Pourgholami MH.

J Oncol. 2012;2012:950749. doi: 10.1155/2012/950749. Epub 2012 Jan 17.

Supplemental Content

Support Center